Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma

NCT00326898 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00326898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00326898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Completed
Start date
April 24, 2006
Completion date
September 1, 2021
Enrollment
1,943 (actual)
Sites
987

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma, stage i renal cell cancer ajcc v6 and v7, stage ii renal cell cancer ajcc v7, stage iii renal cell cancer ajcc v7